"Lymphoma, Large B-Cell, Diffuse" - Books

Result Filters

See Large like-glycosyltransferase in the Gene database

large in Cavia porcellus Saccoglossus kowalevskii Chrysochloris asiatica All 35 Gene records

Results: 1 to 20 of 191 books (1446 items)

<< First< Prev

Page of 10

Next >Last >>

Select item 49075341.

Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Clinical Report [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Aug. (CADTH Optimal Use Report, No. 9.1c.)

Top results in this book Table of Contents

Select item 44036682.

StatPearls [Internet].

Treasure Island (FL): StatPearls Publishing; 2025 Jan-.

Top results in this book Table of Contents

Select item 28215243.

PDQ Cancer Information Summaries [Internet].

Bethesda (MD): National Cancer Institute (US); 2002-.

Top results in this book Table of Contents

Select item 48845144.

Axicabtagene Ciloleucel for Diffuse Large B-Cell Lymphoma: Economic Review Report [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Aug. (CADTH Optimal Use Report, No. 9.1d.)

Top results in this book Table of Contents

Select item 48848125.

Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Ethics and Implementation Report [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Aug. (CADTH Optimal Use Report, No. 9.1e.)

Top results in this book Table of Contents

Select item 42973586.

Non-Hodgkin's Lymphoma: Diagnosis and Management.

National Guideline Alliance (UK).

London: National Institute for Health and Care Excellence (NICE); 2016 Jul. (NICE Guideline, No. 52.)

Top results in this book Table of Contents

Select item 16686907.

Holland-Frei Cancer Medicine. 6th edition.

Kufe DW, Pollock RE, Weichselbaum RR, et al., editors.

Hamilton (ON): BC Decker; 2003.

Top results in this book Table of Contents

Select item 56027568.

$Lisocabtagene Maraleucel (Breyanzi): CADTH Reimbursement Review: Therapeutic area: Relapsed or refractory large B-cell lymphoma [Internet].$

Lisocabtagene Maraleucel (Breyanzi): CADTH Reimbursement Review: Therapeutic area: Relapsed or refractory large B-cell lymphoma [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Oct.

Top results in this book Table of Contents

Select item 55880109.

Tafasitamab (Minjuvi): CADTH Reimbursement Review: Therapeutic area: Diffuse large B-cell lymphoma (DLBCL) [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Jan.

Top results in this book Table of Contents

Select item 570906810.

$Epcoritamab (Epkinly): Therapeutic area: Relapsed or refractory diffuse large B-cell lymphoma: Reimbursement Review [Internet].$

Epcoritamab (Epkinly): Therapeutic area: Relapsed or refractory diffuse large B-cell lymphoma: Reimbursement Review [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Oct.

Top results in this book Table of Contents

Select item 488493811.

Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Health Technology Assessment Introduction and Clinical Review Protocol [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 May. (CADTH Optimal Use Report, No. 9.1a.)

Top results in this book Table of Contents

Select item 563381212.

$Glofitamab (Columvi): CADTH Reimbursement Review: Therapeutic area: Relapsed or refractory diffuse large B-cell lymphoma [Internet].$

Glofitamab (Columvi): CADTH Reimbursement Review: Therapeutic area: Relapsed or refractory diffuse large B-cell lymphoma [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Apr.

Top results in this book Table of Contents

Select item 476155613.

Tisagenlecleucel for B-Cell Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma — Project Protocol, Clinical Section [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Aug. (CADTH Optimal Use Report, No. 8.3a.)

Top results in this book Table of Contents

Select item 476179414.

Tisagenlecleucel for B-Cell Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma — Project Protocol, Implementation and Ethics Section [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Sep. (CADTH Optimal Use Report, No. 8.3b.)

Top results in this book Table of Contents

Select item 530430615.

Lymphoma [Internet].

Gallamini A, Juweid M, editors.

Brisbane (AU): Exon Publications; 2021 Dec 28.

Top results in this book Table of Contents

Select item 488464016.

Axicabtagene Ciloleucel for Large B-cell Lymphoma: Implementation and Ethics Project Protocol [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 May. (CADTH Optimal Use Report, No. 9.1b.)

Top results in this book Table of Contents

Select item 265918217.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet].

York (UK): Centre for Reviews and Dissemination (UK); 1995-.

Top results in this book Table of Contents

Select item 488500018.

Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Recommendations [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Aug. (CADTH Optimal Use Report, No. 9.1f.)

Top results in this book Table of Contents

Select item 560143619.

Polatuzumab Vedotin (Polivy): CADTH Reimbursement Review: Therapeutic area: Large B-cell lymphoma [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Feb.

Top results in this book Table of Contents

Select item 145898420.

GeneReviews® [Internet].

Adam MP, Feldman J, Mirzaa GM, et al., editors.

Seattle (WA): University of Washington, Seattle; 1993-2025.

Top results in this book Table of Contents

<< First< Prev

Page of 10

Next >Last >>

Supplemental Content

Images search in Bookshelf

Figure 5

Histologic and immunophenotypic features of diffuse large B-cell lymphoma. A-E, Diffuse large B-cell lymphoma, NOS, non-germinal center B-cell type, shows sheets of large mostly immunoblast-type tumor cells (A) positive for CD20 (B), BCL6 (D) and MUM1 (E) and negative for CD10 (C). F-J, Primary mediastinal large B-cell lymphoma shows pleomorphic medium to large sized tumor cells in a sclerotic background (F). The tumor cells are positive for CD20 (G), CD30 (H), BCL6 (I) and high Ki67 positivity (J). K-O, Large B-cell lymphoma with IRF4 rearrangement shows sheets of monomorphic medium-sized tumor cells with fine chromatin, multiple basophilic small nucleoli and frequent mitosis (K), diffuse positivity for CD20 (L), MUM1 (M), BCL6 (N), and IRF4 gene rearrangement (O).

Pathogenesis and Pathology of Pediatric Lymphoma.

Gallamini A, Juweid M, editors. Lymphoma [Internet]. Brisbane (AU): Exon Publications; 2021 Dec 28.
Fig. 5.19.3

Established genetic loci for specific lymphoid malignancies. To date, most loci have been discovered in populations of European ancestry. Two loci have been identified in populations of East Asian ancestry: one locus for B-cell lymphoma, particularly diffuse large B-cell lymphoma (DLBCL), and one locus for natural killer/T-cell lymphoma (NKTCL). ALL, acute lymphoblastic leukaemia; CLL, chronic lymphocytic leukaemia; FL, follicular lymphoma; HL, Hodgkin lymphoma; MM, multiple myeloma; MZL, marginal zone lymphoma; NSHL, nodular sclerosing Hodgkin lymphoma; WM, Waldenström macroglobulinaemia.

Non-Hodgkin lymphoma : Complex etiology, including the role of immune function.

Wild CP, Weiderpass E, Stewart BW, editors. World Cancer Report: Cancer research for cancer prevention. Lyon (FR): International Agency for Research on Cancer; 2020.
Figure 3Study Cohorts and Planned Enrolment

DLBCL = diffuse large B-cell lymphoma; PMBCL = primary mediastinal large B-cell lymphoma; TFL = transformed follicular lymphoma.
Source: Information submitted by manufacturer (Clinical Study Report, January 27, 2017, data cut-off).³²

Clinical Review Results.

Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Clinical Report [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Aug.
Figure 130.4

Diffuse large B-cell lymphoma.

Non–Hodgkin’s Lymphomas.

Bast RC Jr, Kufe DW, Pollock RE, et al., editors. Holland-Frei Cancer Medicine. 5th edition. Hamilton (ON): BC Decker; 2000.